A new commercially available DNA strip assay (GenoType Mycobacterium CM/AS; Hain Lifescience, Nehren, Germany) was evaluated for the ability to differentiate mycobacterial species. The test is based on a PCR technique targeting a 23S rRNA gene region, followed by reverse hybridization and line probe technology. The GenoType CM is capable of identifying 23, the GenoType AS a further 14, species either alone or in combination with one or more species. Both tests were evaluated with 156 mycobacterial strains composed of 61 validly published species including different subspecies, 6 not validly published species, and 3 strains other than mycobacterial species. All strains were precharacterized by sequencing of the 5 region of the 16S rRNA gene and biochemical tests. In total, results for 151 strains were interpretable. Concordant results were obtained for 137 (92.6%) of 148 mycobacterial strains with the CM assay and 133 (89.9%) of 148 mycobacterial strains with the AS assay, and all three non-Mycobacterium species were identified.
In recent years, the number of validly described mycobacterial species has increased markedly. The reasons for this are manifold, as some species such as Mycobacterium genavense have newly been identified in immunosuppressed patients, but also include improved culture and detection techniques.
The identification of mycobacteria responsible for a disease and the discrimination of environmental from pathogenic species are relevant diagnostic issues that have important ramifications for the treatment of patients (14, 30) . Since identification to the species level of more than 100 mycobacterial species by classical biochemical methods is too time-consuming and error prone, the introduction of molecular biological methods has greatly improved the speed and accuracy of the process. New DNA sequence-based techniques for the identification of mycobacteria have been developed during the past 10 years, such as DNA sequencing (3, 4, 11) , pyrosequencing (29) , PCR-restriction fragment length polymorphism assays (6, 26, 27) , real-time PCR assays (21) , oligonucleotide arrays (10) , and commercially available tests such as the AccuProbe (Gen-Probe Inc., San Diego, Calif.). Most of these methods require either expensive equipment or extensive expert knowledge or are restricted to a limited number of species that can be identified.
Recently, DNA strip assays for the identification of mycobacteria to the species level have been developed, i.e., the INNO-LiPA MYCOBACTERIA v2 (Innogenetics N.V., Ghent, Belgium) and GenoType Mycobacterium (Hain Lifescience GmbH, Nehren, Germany) assays. These assays are based on reverse hybridization of a PCR product to a nitrocellulose strip with immobilized probes for different mycobacterial species. The INNO-LiPA MYCOBACTERIA v2 assay targets the 16S-to-23S rRNA gene spacer region and provides the identification of 16 different species, whereas the GenoType assay, targeting the 23S rRNA gene region, provides the simultaneous identification of 13 different mycobacterial species. Some evaluation studies have demonstrated the usefulness of both assays for the easy and rapid identification of the majority of common mycobacteria isolated from clinical specimens (7, 9, 19, 20) .
In order to broaden the detection range of mycobacterial species, a new version of the GenoType assay (also targeting the 23S rRNA gene) has been developed, i.e., the combined GenoType Mycobacterium CM/AS assays (CM, common mycobacteria; AS, additional species), which are executed consecutively. The CM assay enables the simultaneous identification of species, including the most relevant M. tuberculosis complex, members of the M. avium complex, M. kansasii, and M. chelonae. Additionally, the second (AS) test provides the identification of species that are found more infrequently, such as M. simiae, M. mucogenicum, and M. celatum. Thus, serial use of the two strips is aimed to identify 35 different patterns, of which 23 patterns can be assigned to single species, 8 patterns are allocated to two or more Mycobacterium species, and 4 patterns correspond to Mycobacterium species and gram-positive bacteria with a high GϩC content.
The objective of this study was to assay whether a variety of relevant mycobacterial strains correctly match the GenoType Mycobacterium CM/AS pattern by investigating 156 strains composed of 83 different species or subspecies. These strains, all identified to the species level, were selected to represent a broad variety of strains. The applicability of the assay in a mycobacterial routine laboratory is discussed.
MATERIALS AND METHODS
Strains analyzed. A set of 156 clinical isolates derived from different patients (n ϭ 153) or cows (n ϭ 3) between 1999 and 2004 was analyzed ( Table 1) . The samples were selected by the following criteria. At least two strains of all species that are detectable with any of the assays were included and tested with both the CM and AS assays. If available, at least two samples of subspecies were selected for the tests. Furthermore, strains that were not detectable with both assays were also included. These strains were composed of validly published mycobacterial species, other mycobacterial strains characterized only by their 16S rRNA gene sequences, and some other closely related species of the genera Corynebacterium, Nocardia, and Rhodococcus (Table 1) . Genotypic characterization. Samples included in the study were selected by routine identification testing of mycobacteria. They were derived from different culture media (liquid or solid). From solid medium, one loopful of cells was suspended in 400 l of distilled water, boiled for 20 min, and sonicated for 15 min. Cells from liquid medium were prepared in the same way but with a preceding centrifugation step. For this, 1 ml of liquid culture medium was centrifuged (10,000 ϫ g, 15 min, room temperature), the supernatant was discarded, and the pellet was suspended in 300 to 500 l of distilled water. All of the samples were stored at Ϫ20°C before further use.
The samples were analyzed by DNA sequencing of the first 500 bp of the 5Ј region of the 16S rRNA gene as described by Richter and colleagues (17) . If identification on the basis of differences in the 16S rRNA gene sequence was not possible, additional analysis of the hsp65 gene (27) or the presence of a specific insertion element was performed (23) . M. tuberculosis complex strains were differentiated by the GenoType MTBC assay (Hain Lifescience GmbH, Nehren, Germany).
GenoType CM/AS assay. The GenoType Mycobacterium CM/AS assay was performed as recommended by the manufacturer. Briefly, for amplification 35 l of a primer-nucleotide mixture (provided with the kit), amplification buffer containing 2.5 mM MgCl 2 , 1.25 U of hot start Taq polymerase (QIAGEN, Hilden, Germany), and 5 l of the heat-inactivated suspension in a final volume of 50 l was used. The amplification protocol consisted of 15 min of denaturing at 95°C, followed by 10 cycles comprising 30 s at 95°C and 120 s at 58°C, an additional 20 cycles comprising 25 s at 95°C, 40 s at 53°C, and 40 s at 70°C, and a final extension at 70°C for 8 min. Hybridization and detection were performed in an automated washing and shaking device (Profiblot; Tekan, Maennedorf, Switzerland). The program was started after mixing 20 l of the amplification products with 20 l of denaturing reagent (provided with the kit) for 5 min in separate troughs of a plastic well. Automatically, 1 ml of prewarmed hybridization buffer was added, followed by a stop to put the membrane strips into each trough. The hybridization procedure was performed at 45°C for 0.5 h, followed by two washing steps. For colorimetric detection of hybridized amplicons, streptavidin conjugated with alkaline phosphatase and substrate buffer was added. After a final washing, strips were air dried and fixed on paper. Each CM and AS strip contains 17 probes including amplification and hybridization controls to verify the test procedures (Fig. 1) . With the CM assay, 15 patterns can be obtained from 23 species (10 individually and 13 in combination), and with the AS assay, 16 patterns can be obtained from 18 species (12 individually and 2 in combination). In the cases of M. marinum and M. ulcerans, the CM assay shows the same pattern for the two species, but with the serial use of the AS assay the two species can be resolved (Fig. 2) . The M. marinum-M. ulcerans pattern in the CM assay was counted as a pattern representing individual species, since it can be resolved with the AS test. A total of 23 patterns attributable to 22 individual species and 8 patterns representing 15 species in combinations of 2 to 4 species can be obtained. In addition, each assay includes two patterns with an amplification control specific for the genus Mycobacterium and one for the detection of all known mycobacteria and members of the group of gram-positive bacteria with a high GϩC content.
Evaluation of the assays was accomplished with a beta version of the kit. In the now commercially available version, the banding pattern was rearranged in order to avoid misinterpretation of identical results of the CM and AS assays. After rechecking of selected samples, we adapted our results to the current interpretation chart.
RESULTS
In this study, 156 clinical isolates composed of 83 different species isolated in Germany between 1999 and 2004 were included. The CM/AS assay is based on a multiplex PCR targeting species-specific DNA regions combined with a reverse hybridization format (DNA strip). The specific patterns are composed of obligatory and additional facultative stainings that can be visually identified by clear-cut hybridization signals on the membrane strips (Fig. 1) . Examples of typical test results are shown in Fig. 2 . Whereas the CM assay allows the identification of at least the most relevant mycobacterial spe- and the universal control line must be positive for a valid result, these five strains were excluded. For all other strains, each band number, which was positive on the CM or AS strip, was noted and the patterns were evaluated to determine the Mycobacterium species according to the interpretation chart provided by the manufacturer (Fig. 1 and Table 1) .
Results of the CM assay. Of 76 strains for which a specific pattern was expected with the CM assay, 74 strains (97.4%) developed the expected pattern (Table 1) . Only two substrains (M. intracellulare serovar 7 and M. kansasii sequevar VI) were not correctly identified by the CM assay. For those strains which were not expected to yield a specific pattern by the assay, the correct result was obtained for 66 (88.0%) out of 75 strains. Mycobacterium sp. strain IWGMT 90242, an M. avium-like strain (31), was correctly negative for the M. avium and M. intracellulare probes and only identified as Mycobacterium sp. For M. parascrofulaceum, a species closely related to M. scrofulaceum, a false result (CM pattern, M. scrofulaceum-"M. paraffinicum") was achieved (Table 1) . For eight strains (six species), recognition as mycobacterial species failed since these strains were only recognized as members of the group of grampositive bacteria with a high GϩC content in their DNA but not as mycobacteria species characterized by specific band 3. The three nonmycobacterial species tested were correctly identified as gram-positive bacteria.
Results of the AS assay. Of the 28 strains included in this study that were expected to produce specific individual or combined patterns in the AS test, 26 strains (92.9%) showed the expected patterns (Table 1) . Whereas M. celatum I and III strains were correctly reactive with the specific M. celatum probes, the two M. celatum II strains were negative. With the AS assay, the definite identification of M. marinum and M. ulcerans could be resolved by a specific probe reacting with M. ulcerans but not with M. marinum (Fig. 2) The results of the AS assay for species that are identifiable with the CM assay only should be Mycobacterium sp. This was obtained for 110 out of 123 strains. One M. fortuitum strain missed specific band 3, the genus control, and was thus identified as a gram-positive bacterium with a high GϩC content but not as a Mycobacterium sp. Furthermore, a weak hybridization signal for M. smegmatis could be observed with this strain, which may be explained by crosshybridization. However, because of the instructions of the manufacturer, the signal was too weak for validation. The only species that is identifiable by both tests is M. kansasii. Whereas most of the subspecies could be clearly identified as M. kansasii also in the AS assay, strains of M. kansasii sequevars VI and III reacted with probes other than that specific for M. kansasii. These results were attributable to neither M. kansasii nor another species. One M. kansasii sequevar VI strain showed only a very weak signal with the M. kansasii probes (not validated). For those strains which are not expected to yield a specific pattern by the AS assay, the correct result was obtained for 66 (88.0%) out of 75 strains. For one not validly described mycobacterial species ("Mycobacterium sp. strain I5"), a false result (AS pattern, M. celatum) was achieved (Table 1 ). In eight strains (six species) that were not recognized as Mycobacterium sp. by the CM assay, recognition as mycobacterial species also failed with the AS assay as these strains were only identified as members of the group of gram-positive bacteria with a high GϩC content in their DNA. However, the three nonmycobacterial species tested were correctly identified as gram-positive bacteria.
DISCUSSION
Early and reliable identification of mycobacteria may provide patients with an earlier onset of proper treatment and may spare patients from unnecessary treatment in the case of growth of environmental species. The conventional biochemical procedures are unable to distinguish more than 100 mycobacterial species since they have overlapping phenotypic patterns (22, 28 genes available for mycobacterial species, differentiation of all species is achievable on the level of DNA sequences. Therefore, efforts for the development of new diagnostic tools for the identification of mycobacterial species by using sequencebased molecular techniques have been undertaken in recent years (3, 4, 6, 10, 11, 21, 26, 27, 29) . These techniques advanced the speed and effectiveness of identification of mycobacterial species grown from clinical specimens.
In this study, we evaluated the GenoType Mycobacterium CM/AS assay, which is intended for the identification of 23 and 14 mycobacterial species either as individual species or in combination with others. In order to test a broad variety of species, 67 different mycobacterial strains (61 validly published species and subspecies and 6 not validly published species) and 3 nonmycobacterial but closely related species were tested. For 92.6% and 89.9% of the isolates, concordant results could be achieved with the CM and AS assays, respectively. Only individual substrains of two species (M. intracellulare serovar 7 and M. kansasii sequevar VI) were not identified by the tests but still identified as mycobacteria. Both species are known for their broad genetic variability (1, 24) . However, with the CM/AS assay, the most common clinical isolates of these groups were identified. For instance, M. kansasii sequevar I represents the most common clinical isolate from humans (1, 25) and also in our laboratory the majority of the clinical strains identified belong to M. kansasii sequevar I. M. kansasii sequevars III, IV, and V have been isolated much less commonly from humans but have been found in environmental samples (1, 12, 32) . Concerning M. intracellulare subspecies, frequencies of isolated strains differ markedly and M. intracellulare serovar 7 belongs to the rarer isolates found in human specimens (18) . Thus, with the CM/AS assay, most of the subspecies were correctly identified through a single banding pattern so that further differentiation with specific probes is not necessary and does not impair the applicability of the test. Subspecies not identified by the assay were at least not classified incorrectly so that the correct final result would be found with subsequent techniques.
A strain that was not recognized by the CM/AS assay but only identified as a Mycobacterium sp. was M. celatum II. This result was not surprising since this strain differs from the other M. celatum I and III strains in the 16S RNA gene sequence and other genetic markers (2, 13) . The discrepancy in the CM/AS assay will be included in future in the manual supplied with the assay (personal communication from the manufacturer). Furthermore, we could show in our study that most of the mycobacterial or other species that cannot be recognized by the CM/AS assay were correctly identified as Mycobacterium sp. or gram-positive bacteria with a high GϩC content. However, eight strains (six species) were identified only as gram-positive bacteria with a high GϩC content and failed to be specified as mycobacterial species with both assays. Thus, evidence of gram-positive bacteria with a high GϩC content does not exclude the concomitance of mycobacteria and has to be evaluated carefully.
The only truly incorrect result that was obtained was the misidentification of a strain not validly published, "Mycobacterium sp. strain I5," as M. celatum, which should be rated as a failure of the assay because of a cross-reaction. Similar discrepancies cannot be excluded because of the broad variety of known and not-yet-known mycobacteria with different DNA sequences in the targeted region. Another fact that should be mentioned is the occurrence of weak background bandings that we observed in some cases. For instance, one M. fortuitum strain correctly identified by the CM assay developed background bandings with the AS assay, which are, however, not assessable according to the instructions of the manufacturer. Nevertheless, this can lead to uncertainty, since an M. kansasii sequevar VI strain also showed weak bands with the AS assay; in this case, they were correct but also not assessable because of their weakness.
Another limitation of the test is the resolution of patterns which represent more than one species, which necessitates other techniques for further discrimination, e.g., biochemical tests, leading to a delay in obtaining a result. Mainly, a species like M. malmoense is rather difficult to identify by other than molecular techniques. If differentiation is desired, DNA analysis of an appropriate target is indispensable.
Recently, in a multicountry survey with 14 participating countries, the frequencies of isolated nontuberculous mycobacteria from clinical laboratories were estimated over a 20-year period. The mycobacterial species most frequently isolated in 1991 to 1996 were the M. avium-M. intracellulare complex (29.1%), M. gordonae (18.8%). M. xenopi (19%), M. kansasii (10.3%), and M. fortuitum (9.8%), accounting for 87.6% of all nontuberculous mycobacteria (8) . The CM assay is able to identify all of these isolates. Thus, together with the other species included on the strips, the CM assay could have identified an estimated 96.4% of the isolates to the species level and a further 0.9% could have been identified with the subsequent AS assay. Therefore, it can be estimated that only a few cases of unusual or unknown mycobacteria will remain unidentified to the species level. Because of the genus probe, these strains can still be identified as mycobacteria or at least as gram-positive bacteria with a high GϩC content. If correct identification to the species level is required, however, DNA sequencing in these rare cases of respective gene fragments is indispensable.
In conclusion, the CM/AS assay allows rapid and specific detection of the most frequently isolated and most relevant species in a mycobacterial diagnostic laboratory. Identification of 37 species (22 individually and 15 as combinations of species) in a sequential analysis represents an important improvement. Moreover, with the sequential application of two different assays the balance between technical feasibility and a high rate of detection of different species is optimal. The clinical performance of these tests may also depend on the prevalence and frequency of nontuberculous mycobacterial species isolated in different countries, and this diversity should therefore be estimated before the test can be implemented as a routine application.
Both the PCR technology and the reverse hybridization technique used for the test have been proven to be robust and reproducible. The results are easy to interpret without extensive expertise such as that required for the application and interpretation of biochemical tests or DNA sequencing. Furthermore, it can easily be implemented in routine work flow, especially when other strip assays are already established, such as the GenoType MTBC for identification and differentiation of the M. tuberculosis complex (15, 16) or the GenoType MTBDR assay for the detection of mutations that are associated with resistance to rifampin and isoniazid (5) . All tests can be run by using the same platform technology. Our results indicate that the CM and AS assays are very useful for the rapid and accurate discrimination of mycobacteria from clinical isolates in a routine mycobacteriological laboratory.
